QTERN™ (saxagliptin/dapagliflozin)

QTERN™ is a fixed dose combination of saxagliptin and dapagliflozin and is indicated in adults aged 18 years and older with type 2 diabetes mellitus1

Position of QTERN™ in the treatment pathway

QTERN™ improves glycaemic control whilst maintaining the additional benefits of FORXIGA®1-5(dapagliflozin)

QTERN™ is for patients on metformin and FORXIGA® who require additional HbA1c reduction.1

Qtern positioning
Qtern positioning

 

QTERN™ combines SGLT2 and DPP-4 inhibition to:1

  • Provide additional HbA1c reduction.1,5
  • Maintain the additional benefits of FORXIGA®1-4
  • Extend oral therapy with a once-daily tablet.1,7

 

QTERN™ has a similar safety profile to its DPP-4 inhibitor and SGLT2 inhibitor monocomponents.1

 

FORXIGA® and QTERN™ are not indicated for the management of weight loss. Weight change was a secondary endpoint in clinical trials.1, 6

FORXIGA® and QTERN™ should not be initiated in patients with an eGFR <60 ml/min/1.73m2.1,6

FORXIGA® 10 mg is associated with low risk of hypoglycaemia when added to metformin. Insulin and insulin secretagogues, such as sulphonylureas, cause hypoglycaemia. Therefore, a lower dose of insulin or an insulin secretagogue may be required to reduce the risk of hypoglycaemia when used in combination with FORXIGA®.6

If QTERN™ is used in combination with insulin secretagogue (sulphonylurea), a reduction in the dose of sulphonylurea may be required to minimise the risk of hypoglycaemia.1

Caution should be exercised in patients for whom a FORXIGA®-induced drop in blood pressure could pose a risk, and also in patients with prior history of UTIs and GIs.6

DPP-4=dipeptidyl peptidase-4; SGLT2=sodium-glucose cotransporter 2.

 

When a metformin plus FORXIGA® patients' disease progresses, replace their FORXIGA® tablet with QTERN™

 

Back to top